Netherlands Translational Research Center B.V.
Oss
About Netherlands Translational Research Center B.V.
NTRC is a precision medicine company dedicated to the development of new anti-cancer drugs. NTRC facilitates the development of novel therapies by providing cancer cell line profiling services (Oncolines™, OncolinesProfiler™, SynergyFinder™ and SynergyScreen™) and target residence time measurements for protein kinases (ResidenceTimer™) on a fee-for-service basis. NFK GreenScreen™, an assay read-out for the cancer immunotherapy drug targets IDO1 and TDO, is supplied to clients globally. NTRC has internal drug discovery programs on TTK, IDO1, and TDO.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $60.2K
- Last round: Grant (Jan 2015)
- Website: ntrc.nl
- Phone: +31 412 700500
Industries & Categories
Biotechnology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/netherlands-translational-research-center-b-v-2210557 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.